Viral Hepatitis

You have full text access to this OnlineOpen article

Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection†

  1. Martin Lagging1,‡,*,
  2. Nina Langeland2,
  3. Court Pedersen3,
  4. Martti Färkkilä4,
  5. Mads Rauning Buhl5,
  6. Kristine Mørch2,
  7. Amar P. Dhillon6,
  8. Åsa Alsiö1,
  9. Kristoffer Hellstrand1,
  10. Johan Westin1,
  11. Gunnar Norkrans1

Article first published online: 1 FEB 2008

DOI: 10.1002/hep.22253

Issue

Hepatology

Hepatology

Volume 47, Issue 6, pages 1837–1845, June 2008

Additional Information

How to Cite

Lagging, M., Langeland, N., Pedersen, C., Färkkilä, M., Buhl, M. R., Mørch, K., Dhillon, A. P., Alsiö, Å., Hellstrand, K., Westin, J. and Norkrans, G. (2008), Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology, 47: 1837–1845. doi: 10.1002/hep.22253

Author Information

  1. 1

    Department of Infectious Diseases, Göteborg University, Göteborg, Sweden

  2. 2

    Department of Infectious Diseases, Haukeland University Hospital and Institute of Medicine, University of Bergen, Bergen, Norway

  3. 3

    Department of Infectious Diseases, University of Southern Denmark, Southern Denmark, Denmark

  4. 4

    Department of Gastroenterology, Helsinki University, Helsinki, Finland

  5. 5

    Department of Infectious Diseases, Aarhus University, Aarhus, Denmark

  6. 6

    Department of Histopathology, Royal Free Hospital, London, United Kingdom

  1. ‡

    fax: +46-31-41 12 56

*Department of Infectious Diseases, Göteborg University, Guldhedsgatan 10B, SE-413 46 Göteborg, Sweden

  1. †

    Potential conflict of interest: Dr. Lagging is a consultant for Schering-Plough, Roche, and Abbott.

Publication History

  1. Issue published online: 28 MAY 2008
  2. Article first published online: 1 FEB 2008
  3. Accepted manuscript online: 1 FEB 2008 12:00AM EST
  4. Manuscript Accepted: 23 JAN 2008
  5. Manuscript Received: 27 AUG 2007

Funded by

  • Swedish Society of Medicine
  • Swedish Medical Research Council
  • Swedish Society of Microbiology
  • Avtal om läkarutbildning och forskning (ALF) Funds. Grant Number: ALFGBG-3149
  • Roche affiliates in the Nordic region

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (377K)

References

  • 1
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–362.
  • 2
    Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494–1500.
  • 3
    Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990; 87: 6547–6549.
  • 4
    Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, Lindh M, et al. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002; 22: 136–144.
    Direct Link:
  • 5
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 6
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 7
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
  • 8
    Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 40: 1260–1265.
    Direct Link:
  • 9
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609–2617.
  • 10
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522–527.
  • 11
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124–134.
  • 12
    Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. J Clin Virol 2005; 34: 108–114.
  • 13
    Westin J, Lagging LM, Wejstal R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 183–187.
    Direct Link:
  • 14
    Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250–257.
  • 15
    Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol 2006; 45: 539–546.
  • 16
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
  • 17
    Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837–842.
View Full Article (HTML) Get PDF (377K)